Drug Search Results
More Filters [+]

Oglufanide

Alternative Names: oglufanide
Latest Update: 2014-05-22
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: VEGF Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Inhalant

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Implicit Bioscience
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Oglufanide

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Hepatitis C, Chronic

Phase 1: Ovarian Cancer|Hepatitis C, Chronic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CDR0000066900 (5O-98-4)

P1

Completed

Ovarian Cancer

2000-07-01

ACTRN12606000505505

P1

Terminated

Hepatitis C, Chronic

None

ACTRN12607000418471

P2

Completed

Hepatitis C, Chronic

None

Recent News Events

Date

Type

Title